Haemonetics Corporation (HAE)
| Market Cap | 3.06B -13.3% |
| Revenue (ttm) | 1.33B -2.0% |
| Net Income | 97.31M -42.0% |
| EPS | 2.05 -38.1% |
| Shares Out | 45.45M |
| PE Ratio | 33.06 |
| Forward PE | 12.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,494 |
| Open | 66.98 |
| Previous Close | 67.04 |
| Day's Range | 66.19 - 68.33 |
| 52-Week Range | 47.32 - 87.32 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 81.60 (+21.23%) |
| Earnings Date | May 7, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management syst... [Read more]
Financial Performance
In fiscal year 2026, Haemonetics's revenue was $1.33 billion, a decrease of -1.97% compared to the previous year's $1.36 billion. Earnings were $97.31 million, a decrease of -41.97%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $81.6, which is an increase of 21.23% from the latest price.
News
Haemonetics price target raised to $70 from $64 at Citi
Citi raised the firm’s price target on Haemonetics (HAE) to $70 from $64 and keeps a Neutral rating on the shares. The firm updated models in the medical technology space…
Haemonetics upgraded to Buy at BofA on upside to guidance
As previously reported, BofA analyst Travis Steed upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $80, up from $72. The firm, which thinks that it seems…
Haemonetics upgraded to Buy from Neutral at BofA
BofA upgraded Haemonetics (HAE) to Buy from Neutral with a price target of $80, up from $72.
Haemonetics Transcript: Bank of America Global Healthcare Conference 2026
Management highlighted robust revenue and margin growth, driven by core products and innovation in plasma and hospital businesses. Vascular closure is rebounding, and blood management technologies are accelerating. The company is focused on organic growth, margin expansion, and capital returns.
Haemonetics price target lowered to $89 from $94 at Barrington
Barrington lowered the firm’s price target on Haemonetics (HAE) to $89 from $94 and keeps an Outperform rating on the shares citing somewhat lower profitability expectations for FY27 based on…
Haemonetics Q4 Earnings Call Highlights
Haemonetics NYSE: HAE reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies bu...
Haemonetics price target lowered to $67 from $72 at Baird
Baird analyst David Rescott lowered the firm’s price target on Haemonetics (HAE) to $67 from $72 and keeps an Outperform rating on the shares. The firm updated its model following…
Haemonetics price target lowered to $62 from $74 at JPMorgan
JPMorgan lowered the firm’s price target on Haemonetics (HAE) to $62 from $74 and keeps a Neutral rating on the shares.
Haemonetics Earnings Call Transcript: Q4 2026
Q4 and full-year results showed strong organic growth, margin expansion, and robust free cash flow, driven by Plasma and TEG platforms. Fiscal 2027 guidance projects continued revenue and margin growth, with innovation and portfolio transformation supporting future performance.
Haemonetics Earnings release: Q4 2026
Haemonetics released its Q4 2026 earnings on May 7, 2026, summarizing the period's financial results.
Haemonetics Slides: Q4 2026
Haemonetics has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 7, 2026.
Haemonetics Annual report: Q4 2026
Haemonetics has published its Q4 2026 annual report on May 7, 2026.
Haemonetics reports Q4 adjusted EPS $1.29, consensus $1.27
Reports Q4 revenue $346.35M, consensus $336.86M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma...
Haemonetics sees FY27 adjusted EPS up 4%-7%
Sees FY27 revenue up 4%-7%. Sees FY27 free cash flow conversion 80%.
Haemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal...
Haemonetics to Present at Bank of America 2026 Healthcare Conference
BOSTON, May 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Bank of America 2026 He...
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
BOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today a...
Haemonetics price target lowered to $70 from $80 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on Haemonetics (HAE) to $70 from $80 and keeps an Outperform rating on the shares. The firm lowered estimates and price…
Haemonetics price target lowered to $84 from $88 at BTIG
BTIG lowered the firm’s price target on Haemonetics (HAE) to $84 from $88 and keeps a Buy rating on the shares as part of a broader research name on Medical…
Haemonetics price target lowered to $64 from $70 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $64 from $70 and keeps a Neutral rating on the shares. The firm adjusted targets in the…
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May...
Haemonetics: FDA approves expanded labeling for VASCADE MVP XL system
Haemonetics (HAE) announced U.S. FDA approval to expand the labeling for the VASCADE MVP XL venous vascular closure system to include procedures using 10-14F inner diameter and up to 17F…
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System
VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology ...
Haemonetics price target lowered to $70 from $75 at Citi
Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $70 from $75 and keeps a Neutral rating on the shares. The firm adjusted targets in the…
Haemonetics Transcript: 47th Annual Raymond James Institutional Investor Conference
The conference highlighted record plasma business growth, successful innovation cycles, and robust financial performance, with strong share gains and new product launches like Persona PLUS and PerQseal Elite. The company is focused on sustainable growth, operational improvements, and disciplined capital deployment.